245 related articles for article (PubMed ID: 35582653)
1. New horizons for uncommon mutations in non-small cell lung cancer:
Olmedo ME; Cervera R; Cabezon-Gutierrez L; Lage Y; Corral de la Fuente E; Gómez Rueda A; Mielgo-Rubio X; Trujillo JC; Couñago F
World J Clin Oncol; 2022 Apr; 13(4):276-286. PubMed ID: 35582653
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
König D; Savic Prince S; Rothschild SI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671873
[TBL] [Abstract][Full Text] [Related]
5. Beyond
Farago AF; Azzoli CG
Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
[TBL] [Abstract][Full Text] [Related]
6. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
7. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer.
Tartarone A; Lapadula V; Di Micco C; Rossi G; Ottanelli C; Marini A; Giorgione R; Ferrari K; Catalano M; Voltolini L; Mini E; Roviello G
Front Oncol; 2021; 11():632256. PubMed ID: 34094913
[TBL] [Abstract][Full Text] [Related]
8. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
9. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Lamberti G; Andrini E; Sisi M; Rizzo A; Parisi C; Di Federico A; Gelsomino F; Ardizzoni A
Crit Rev Oncol Hematol; 2020 Dec; 156():103119. PubMed ID: 33053439
[TBL] [Abstract][Full Text] [Related]
10. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z; Xing Y; Li B; Li X; Liu B; Wang Y
Mol Biomed; 2022 Dec; 3(1):42. PubMed ID: 36508072
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than
Seegobin K; Majeed U; Wiest N; Manochakian R; Lou Y; Zhao Y
Front Oncol; 2021; 11():750657. PubMed ID: 34926258
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
Rothschild SI
Cancers (Basel); 2015 May; 7(2):930-49. PubMed ID: 26018876
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics of
Dugay F; Llamas-Gutierrez F; Gournay M; Medane S; Mazet F; Chiforeanu DC; Becker E; Lamy R; Léna H; Rioux-Leclercq N; Belaud-Rotureau MA; Cabillic F
Oncotarget; 2017 Aug; 8(32):53336-53351. PubMed ID: 28881815
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Bansal P; Osman D; Gan GN; Simon GR; Boumber Y
Front Oncol; 2016; 6():112. PubMed ID: 27200298
[TBL] [Abstract][Full Text] [Related]
17. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
18. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
19. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
20. Targeting molecular alterations in non-small-cell lung cancer: what's next?
López-Castro R; García-Peña T; Mielgo-Rubio X; Riudavets M; Teixidó C; Vilariño N; Couñago F; Mezquita L
Per Med; 2022 Jul; 19(4):341-359. PubMed ID: 35748237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
